Albert Arnaiz-Camacho

Dr. Albert Arnaiz-Camacho

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 November 2024 in European Journal of Ophthalmology
Verified
Journal Article
Closed access
YBYann Bertolani
Yann Bertolani
AAAlbert Arnaiz-Camacho
Albert Arnaiz-Camacho
JFJorge Fernández-Engroba
Jorge Fernández-Engroba
JGJose García-Arumí
Jose García-Arumí
MZMiguel-Ángel Zapata
Miguel-Ángel Zapata
Purpose: To describe the successful use of plasma rich in growth factors (PRGF-Endoret®) and internal limiting membrane peeling for full thickness macular hole in Macular Telangiectasia type 2. Case presentation: A case report of a full thickness macular hole (FTMH) associated with Macular Telangiectasia (MacTel) type 2 is described. 25-G vitrectomy with internal limiting membrane (ILM) peeling and use of (PRGF-Endoret®) was performed. Several ophthalmological visits were conducted and multiple diagnostic tests were carried out including optical coherence tomography (OCT) and fluorescein angiography. A 72-year-old man under follow-up for MacTel type 2 presented with worsening vision in his left eye, with a best visual corrected acuity (BVCA) of 20/80. OCT demonstrated a FTMH in the left eye measuring 264 µm. A 25-gauge pars plana vitrectomy surgery was performed with ILM peeling, use of PRGF-Endoret® and tamponade with 20% sulfur hexafluoride (SF6). Three weeks after surgery, complete anatomical closure was observed with a BVCA of 20/40, which improved to 20/25 one year after the surgery. Conclusions: The use of PRGF associated with ILM peeling may be a useful tool in the treatment of macular holes associated with MacTel Type 2 with excellent anatomical and functional outcomes.

11 June 2026 in Family Practice
Verified
Journal Article
Closed access
AAAlbert Arnaiz-Camacho
Albert Arnaiz-Camacho
MCMarta Castany-Aregall
Marta Castany-Aregall
APArmand Pairó-Salvador
Armand Pairó-Salvador
SGSara García-Hidalgo
Sara García-Hidalgo
TPTatiana Pablos-Jiménez
Tatiana Pablos-Jiménez
MZMiguel-Ángel Zapata
Miguel-Ángel Zapata
To describe a novel screening tool for the detection of visual alterations in primary care. A prospective study was conducted in order to assess concordance and feasibility of the Amapola Test. In patients with a visual complaint, a primary care resident physician identified the visual symptom using the Amapola Test and the results were then compared with an expert history-taking conducted by an ophthalmologist. The Amapola Test was administered to 350 patients with visual disturbances. Of these, 321 patients identified the symptom on the visual charts. The test showed a high concordance rate, with a usability of 89.4% (95% CI: 86.2%-92.6%). The most frequently identified visual symptoms were blurred vision (109), isolated floaters (75), floaters combined with photopsia (23), and isolated photopsia (20). The most common diagnoses were posterior vitreous detachment (100), migraine visual aura (28), and exudative age-related macular degeneration (19). The Amapola Test allows for correct identification of visual symptoms. This study demonstrates a high level of concordance between patient-reported symptoms using the test and expert clinical history, and indicates potential application as a supportive tool in primary care. However, further studies in real-life settings are needed to demonstrate its usefulness and to evaluate its diagnostic performance. not applicable.

28 July 2026 in European Journal of Ophthalmology
Verified
Journal Article
Closed access
RGRocío García-Risco
Rocío García-Risco
AAAlbert Arnaiz-Camacho
Albert Arnaiz-Camacho
SNSara Martín Nalda
Sara Martín Nalda
LBLaia Bisbe
Laia Bisbe
JGJavier José Puig Galy
Javier José Puig Galy
APAlfredo Pueyo
Alfredo Pueyo

31 January 2025 in Archivos de la Sociedad Española de Oftalmología
Verified
Journal Article
Closed access
AAAlbert Arnaiz-Camacho
Albert Arnaiz-Camacho
CPC. Parés-Alfonso
C. Parés-Alfonso
LSL. Sánchez-Vela
L. Sánchez-Vela

28 February 2025 in Medicina de Familia. SEMERGEN
Verified
Journal Article
Closed access
RRR. García Risco
R. García Risco
PEP. Buck Espel
P. Buck Espel
AAAlbert Arnaiz-Camacho
Albert Arnaiz-Camacho
PVP. García Valentín
P. García Valentín
MZMiguel Angel Zapata
Miguel Angel Zapata

Verified
Journal Article
Open access
PDF file
CFCarmen Antía Rodríguez Fernández
Carmen Antía Rodríguez Fernández
DODavid Oliver-Gutierrez
David Oliver-Gutierrez
AAAlbert Arnaiz-Camacho
Albert Arnaiz-Camacho
TJTatiana Pablos Jimenez
Tatiana Pablos Jimenez
GSGloria Segura-Duch
Gloria Segura-Duch
MZMiguel Angel Zapata
Miguel Angel Zapata
Background: Intravitreal injections (IVI) are widely used for the management of retinal diseases, yet younger adults are underrepresented in clinical trials and real-world reports. Data on the etiologic distribution and treatment patterns of IVI in patients aged ≤50 years remain limited. This study aimed to characterize the indications, treatment strategies, and visual outcomes of IVI in this age group. Material and Methods: Retrospective, single-center observational study including adults aged 18–50 years who received IVI between January 2020 and December 2023 at a tertiary referral hospital in Spain. Demographic data, diagnosis, treatment modality, regimen, number of injections and best-corrected visual acuity (BCVA) were collected. One eye per patient was included for analysis. Visual outcomes were assessed as change in logMAR BCVA between baseline and final follow-up. Results: A total of 122 patients were included. The most frequent indications were diabetic macular edema (29.5%), macular neovascularization of various etiologies (21.3%), retinal vein occlusion (13.9%) and uveitis (9.8%). Anti-vascular endothelial growth factor (anti-VEGF) agents were used in 80.3% of eyes, corticosteroids in 6.6% and combination therapy in 13.1%. The mean number of injections per patient was 6.0 ± 5.3 over a mean follow-up of 3.0 ± 2.5 years. Overall BCVA improved significantly from 0.50 ± 0.59 to 0.38 ± 0.50 logMAR (p = 0.012). Conclusions: IVI in adults ≤ 50 years is uncommon but encompasses a broad etiologic spectrum. Diabetic macular edema and macular neovascularization of diverse etiologies were the leading indications. Anti-VEGF therapy represented the main treatment modality in this cohort.